SEED FONDS I AACHEN SELLS SHARES IN BIOTECHNOLOGY COMPANY M2P-LABS GMB - S-UBG
string(13) "center center"

SEED FONDS I AACHEN SELLS SHARES IN BIOTECHNOLOGY COMPANY M2P-LABS GMB

Aachen-based start-up goes to life science group Beckman Coulter and further expands market leadership

Aachen, 16 November 2020 – The “Seed Fonds I für die Region Aachen GmbH & Co. KG” (Seed Fonds Aachen), together with lead investors FIDURA, KfW Bankengruppe, Hightech Gründerfonds and other private investors, has sold its shares in Aachen-based startup m2p-labs GmbH to Beckman Coulter Life Science. This brings to an end of a twelve-year investment partnership that began in 2008 when the Seed Fund, the predecessor of TechVisions Fund I, invested in the biotechnology company and continued in 2011 with a further financing round. With the sale to a strategic partner from the biotech industry, m2p-labs is in a position to take the potential of its product portfolio to the next level. We are delighted to be able to hand over another of our long-standing portfolio companies into good hands,” says Harald Heidemann, managing director of the S-UBG Group.

Investor consortium an important sparring partner so far

m2p-labs GmbH emerged as a spin-off from RWTH Aachen University in 2005 and is one of the leading providers of analysers for carrying out high-throughput cellular screening in the field of bioprocess development. The patented technology made it possible for the first time to record important process parameters online, non-invasively and in a highly parallel manner without interrupting the screening process. It is suitable for tasks such as strain selection, promoter characterisation and culture media optimisation. m2p-labs’ customers primarily come from the pharmaceutical, biotechnology and chemical industries. “The investor consortium has been a good financing and sparring partner for the m2p team over the years,” says Dr Christoph Petry, Managing Director of m2p-labs GmbH. “This has not only enabled us to grow continuously and establish our market leadership in the field of bioprocessing and develop a unique microfluidic chip technology, but also to optimise our internal processes.”Beckman Coulter Life Science expands its product portfolio

By acquiring the shares in m2p-labs GmbH, Beckman Coulter Life Science is expanding its product range in the areas of liquid handling and laboratory automation. The aim is to realise efficient systems for cell line development and process workflow more quickly together with the Aachen-based start-up’s team. Beckman Coulter is one of the world’s leading manufacturers of measuring instruments and test assays in the field of clinical diagnostics and life science. The company is headquartered in Brea, California. The company employs over 10,000 people worldwide. It has been represented in Germany for 65 years with its headquarters in Krefeld.

Beckman Coulter Life Science expands its product portfolio

By acquiring shares in m2p-labs GmbH, Beckman Coulter Life Science is expanding its product spectrum in the areas of liquid handling and laboratory automation. The aim is to realise efficient cell line development and process workflow systems more quickly together with the Aachen-based start-up’s team. Beckman Coulter is one of the world’s leading manufacturers of measuring instruments and test assays in the field of clinical diagnostics and life science. The company is headquartered in Brea, California. The company employs over 10,000 people worldwide. It has been represented in Germany for 65 years with its headquarters in Krefeld.